Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.41 |
| ▸ | JAK3 | P52333 | 13/20 | 0.38 |
| ▸ | JAK2 | O60674 | 12/20 | 0.38 |
| ▸ | JAK1 | P23458 | 12/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280574 | 0.80 | MAPK1 (0.50) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2275777 | 0.78 | LDHB (0.50) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2274537 | 0.77 | SYK (0.48) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2280589 | 0.74 | SYK (0.71) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2282167 | 0.73 | JAK2 (0.43) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL652225 | 0.73 | MAPK1 (0.47) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL12441730 | 0.73 | JAK3 (0.43) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2282266 | 0.71 | CDK8 (0.47) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL2279424 | 0.71 | JAK3 (0.51) | SYKJAK3JAK2JAK1CYP2C9 | |
| SCHEMBL1634965 | 0.71 | SYK (0.46) | SYKJAK3JAK2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | SYK 1/4885JAK3 7/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.